The role of GLP-1 receptor agonists in managing type 2 diabetes

Noura Nachawi; Pratibha Pr Rao; Vinni Makin

doi:10.3949/ccjm.89a.21110

The role of GLP-1 receptor agonists in managing type 2 diabetes

Cleve Clin J Med. 2022 Aug 1;89(8):457-464. doi: 10.3949/ccjm.89a.21110.

Authors

Noura Nachawi¹, Pratibha Pr Rao², Vinni Makin³

Affiliations

¹ Department of Endocrinology, Diabetes, and Metabolism, Cleveland Clinic, Cleveland, OH.
² Quality Improvement Officer, Endocrinology and Metabolism Institute, Cleveland Clinic, Cleveland, OH; Clinical Assistant Professor, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, Cleveland, OH.
³ Director, East Region, Department of Endocrinology, Diabetes, and Metabolism, Cleveland Clinic; Assistant Professor of Medicine, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, Cleveland, OH makinv@ccf.org.

PMID: 35914933
DOI: 10.3949/ccjm.89a.21110

Abstract

Glucagon-like peptide-1 (GLP-1) receptor agonists improve glycemic control in patients with type 2 diabetes mellitus, have cardioprotective and renoprotective effects, and do not cause weight gain or significant hypoglycemia. In fact, they have been found to be effective for weight loss in patients with obesity with and without diabetes. They are now the preferred drugs to add to the regimen when oral metformin by itself is not enough to meet the patient's hemoglobin A1c goal.

Publication types

Review

MeSH terms

Diabetes Mellitus, Type 2* / complications
Diabetes Mellitus, Type 2* / drug therapy
Glucagon-Like Peptide-1 Receptor / agonists
Glycated Hemoglobin / analysis
Humans
Hypoglycemia*
Hypoglycemic Agents / pharmacology
Hypoglycemic Agents / therapeutic use

Substances

GLP1R protein, human
Glucagon-Like Peptide-1 Receptor
Glycated Hemoglobin A
Hypoglycemic Agents